Jazz to Withdraw Zepzelca Second-Line SCLC Approval After Second Confirmatory Trial Failure

Update September 10, 2026: Amgen’s Imdelltra plus AstraZeneca’s Imfinzi met the overall survival primary endpoint in the Phase 3 DeLLphi-305 trial as first-line maintenance for extensive-stage SCLC (announced September 8) — see our coverage. That readout sharpens the threat to Zepzelca’s first-line maintenance indication, which this article identifies as its “sole growth driver.” Full hazard-ratio data is pending.

Jazz Pharmaceuticals (JAZZ) will voluntarily withdraw Zepzelca’s (lurbinectedin) accelerated approval in second-line small cell lung cancer after the Phase 3 LAGOON trial failed to meet its overall survival primary endpoint. The withdrawal, which Jazz plans to submit in Q3 2026, does not affect the drug’s separate first-line maintenance approval with Roche’s Tecentriq. JAZZ shares closed at $256.56 on August 7.

Zepzelca received accelerated approval in June 2020 based on a 35% overall response rate in a 105-patient single-arm trial. The FDA required confirmatory trials as a condition of staying on the market. The first confirmatory attempt, the Phase 3 Atlantis trial testing lurbinectedin plus doxorubicin, failed in 2021. The FDA allowed the drug to remain available, citing use of a lower dose in Atlantis and unmet need in the second-line setting.

The LAGOON trial (N=724) was the second attempt, testing standard-dose Zepzelca monotherapy and Zepzelca plus irinotecan against the investigator’s choice of topotecan or irinotecan. The monotherapy arm performed worse than the control arm. The combination arm showed a numerical advantage that did not reach statistical significance. With two confirmatory failures and Amgen’s Imdelltra now approved as standard therapy in previously treated SCLC, the FDA’s case for allowing a third chance evaporated.

Zepzelca still generated $106 million in Q2 2026 revenue, up 42% year over year. But 60% to 70% of that came from second-line use, according to Jazz’s chief commercial officer on the Q2 earnings call. The withdrawal opens a revenue gap the first-line maintenance indication must fill. Second-line prescribing had already been declining due to competition and Jazz expects it to “accelerate” now.

The first-line maintenance indication, approved in 2025 based on the IMforte trial, is now Zepzelca’s sole growth driver. That trial showed a statistically significant overall survival benefit for lurbinectedin plus Tecentriq versus Tecentriq alone in extensive-stage SCLC. But the commercial ramp of the maintenance regimen has been slower than the second-line business it must replace, and Jazz faces the task of convincing oncologists to adopt the combination in a setting where Tecentriq alone isn’t standard of care.

The story is part of a broader FDA push to enforce confirmatory trial requirements for accelerated approvals. GSK withdrew Blenrep in 2022 after its confirmatory trial failed; Gilead pulled Trodelvy’s bladder cancer indication on similar grounds. Zepzelca’s saga is notable for lasting six years and surviving one failed confirmatory trial before the FDA drew the line at a second miss.

Jazz’s other major catalyst — the FDA decision on zanidatamab (Ziihera) for first-line gastroesophageal adenocarcinoma — resolved on August 25 with approval. Read our Ziihera approval coverage and the pre-decision analysis.

Source: Jazz Pharmaceuticals Q2 2026 earnings / FiercePharma

What It Means for the Trade

The withdrawal converts a $106-million-per-quarter and growing franchise into a maintenance-only story, and the market’s job is now pricing what remains. The math is unforgiving: 60-70% of current Zepzelca revenue is second-line, so roughly $65-75 million a quarter evaporates as inventory and prescriptions run down, and the first-line maintenance indication must ramp from a smaller base to fill the gap. Jazz management’s own guidance that second-line decline will “accelerate” is code for a 2027 revenue hole.

Mechanism and Market Context

Lurbinectedin is a transcription-factor inhibitor that blocks RNA-polymerase-mediated transcription in tumor cells — a mechanism with single-agent activity in SCLC that never translated into randomized survival. The 2020 accelerated approval rested on a 35% response rate in a 105-patient single-arm study; Atlantis (with doxorubicin) failed in 2021; LAGOON’s monotherapy arm underperformed topotecan and the combination arm missed significance. Six years of market presence on an unconfirmed surrogate is the cautionary tale — efficacy signals from single-arm studies in refractory populations routinely fail to survive randomized comparison, and SCLC second-line is a graveyard of exactly such programs.

The IMforte-based maintenance approval is the surviving economic asset, and its biology is sounder: combining lurbinectedin with Tecentriq in first-line maintenance rides the immunotherapy backbone oncologists already use. But the September DeLLphi-305 readout (Imdelltra plus Imfinzi maintenance) is now the swing event for that whole setting — if the DLL3-targeted bispecific combination wins overall survival, the maintenance standard shifts and Zepzelca’s remaining growth engine gets priced competitively from day one.

Risks and What Could Go Wrong

1. DeLLphi-305 displacement. A positive Amgen/AstraZeneca OS readout could relegate lurbinectedin-Tecentriq to second-line maintenance choice and cap the ramp that replaces the withdrawn revenue.
2. Transition-year guidance. The gap between second-line runoff and maintenance uptake lands squarely in 2027 estimates; watch for guidance cuts at the next print.
3. Prescriber habit decay. Even absent formal withdrawal friction, an announced withdrawal tells community oncologists to move on — Jazz must win the maintenance argument in real time.
4. Portfolio concentration. With Zepzelca shrinking, Jazz leans harder on Ziihera and sleep; execution stumbles there amplify the SCLC loss.

Net: a well-managed but structural revenue hole. Trade the maintenance ramp data and DeLLphi-305 as the next legs; the withdrawal itself is now priced.